Peter Park
Peter Park, PhD
Professor of Biomedical Informatics, Harvard Medical School
10 Shattuck Street, Boston, MA 02115

Peter Park is director of the HMS Bioinformatics and Integrative Genomics (BIG) PhD program. His Computational Genomics group specializes in computational and statistical analysis of high-throughput sequencing data to understand genetic and epigenetic mechanisms related to disease processes, especially in cancer. Originally trained in applied mathematics, Park earned a PhD, from Caltech and was introduced to molecular biology and genetics during his postdoctoral studies in biostatistics. His laboratory has developed several algorithms for chromatin and genome analysis and has made major contributions to large NIH consortium projects such as the model organism ENCyclopedia of DNA Elements (modENCODE) and The Cancer Genome Atlas. He has also collaborated with dozens of experimentalists over the years to study a wide range of genetic and epigenetic phenomena and their alterations, both in humans and in model organisms. He is a member of the Division of Genetics at Brigham and Women's Hospital, co-leader of the Biostatistics and Computational Biology Program at the Dana-Farber/Harvard Cancer Center, and director of the Center for Stem Cell Bioinformatics at the Harvard Stem Cell Institute.


DBMI Research Areas
DBMI Courses
Tibanna: software for scalable execution of portable pipelines on the cloud.
Authors: Lee S, Johnson J, Vitzthum C, Kirli K, Alver BH, Park PJ.
Bioinformatics
View full abstract on Pubmed
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease.
Authors: Kim J, Hu C, Moufawad El Achkar C, Black LE, Douville J, Larson A, Pendergast MK, Goldkind SF, Lee EA, Kuniholm A, Soucy A, Vaze J, Belur NR, Fredriksen K, Stojkovska I, Tsytsykova A, Armant M, DiDonato RL, Choi J, Cornelissen L, Pereira LM, Augustine EF, Genetti CA, Dies K, Barton B, Williams L, Goodlett BD, Riley BL, Pasternak A, Berry ER, Pflock KA, Chu S, Reed C, Tyndall K, Agrawal PB, Beggs AH, Grant PE, Urion DK, Snyder RO, Waisbren SE, Poduri A, Park PJ, Patterson A, Biffi A, Mazzulli JR, Bodamer O, Berde CB, Yu TW.
N Engl J Med
View full abstract on Pubmed
Global impact of somatic structural variation on the DNA methylome of human cancers.
Authors: Zhang Y, Yang L, Kucherlapati M, Hadjipanayis A, Pantazi A, Bristow CA, Lee EA, Mahadeshwar HS, Tang J, Zhang J, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Park PJ, Kucherlapati R, Creighton CJ.
Genome Biol
View full abstract on Pubmed
Author Correction: BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.
Authors: Wang X, Wang S, Troisi EC, Howard TP, Haswell JR, Wolf BK, Hawk WH, Ramos P, Oberlick EM, Tzvetkov EP, Ross A, Vazquez F, Hahn WC, Park PJ, Roberts CWM.
Nat Commun
View full abstract on Pubmed
Identification of somatic mutations in single cell DNA-seq using a spatial model of allelic imbalance.
Authors: Luquette LJ, Bohrson CL, Sherman MA, Park PJ.
Nat Commun
View full abstract on Pubmed
Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors.
Authors: Oberlick EM, Rees MG, Seashore-Ludlow B, Vazquez F, Nelson GM, Dharia NV, Weir BA, Tsherniak A, Ghandi M, Krill-Burger JM, Meyers RM, Wang X, Montgomery P, Root DE, Bieber JM, Radko S, Cheah JH, Hon CS, Shamji AF, Clemons PA, Park PJ, Dyer MA, Golub TR, Stegmaier K, Hahn WC, Stewart EA, Schreiber SL, Roberts CWM.
Cell Rep
View full abstract on Pubmed
An enhanced genetic model of colorectal cancer progression history.
Authors: Yang L, Wang S, Lee JJ, Lee S, Lee E, Shinbrot E, Wheeler DA, Kucherlapati R, Park PJ.
Genome Biol
View full abstract on Pubmed
Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma.
Authors: Lee JJ, Park S, Park H, Kim S, Lee J, Lee J, Youk J, Yi K, An Y, Park IK, Kang CH, Chung DH, Kim TM, Jeon YK, Hong D, Park PJ, Ju YS, Kim YT.
Cell
View full abstract on Pubmed
BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.
Authors: Wang X, Wang S, Troisi EC, Howard TP, Haswell JR, Wolf BK, Hawk WH, Ramos P, Oberlick EM, Tzvetkov EP, Vazquez F, Hahn WC, Park PJ, Roberts CWM.
Nat Commun
View full abstract on Pubmed
Detecting the mutational signature of homologous recombination deficiency in clinical samples.
Authors: Gulhan DC, Lee JJ, Melloni GEM, Cortés-Ciriano I, Park PJ.
Nat Genet
View full abstract on Pubmed